Cambridge Antibody Tech Group PLC
07 March 2005
SCHEDULE 11
NOTIFICATION OF INTERESTS OF DIRECTORS AND CONNECTED PERSONS
1) Name of company
Cambridge Antibody Technology
2) Name of director
Peter Chambre
3) Please state whether notification indicates that it is in respect of
holding of the shareholder named in 2 above or in respect of a
non-beneficial interest or in the case of an individual holder if it is a
holding of that person's spouse or children under the age of 18 or in respect of
a non-beneficial interest
As in 2 Above
4) Name of the registered holder(s) and, if more than one holder, the
number of shares held by each of them (if notified)
As in 2 above
5) Please state whether notification relates to a person(s) connected
with the Director named in 2 above and identify the connected person(s)
As in 2 above
6) Please state the nature of the transaction. For PEP transactions
please indicate whether general/single co PEP and if discretionary/non
discretionary
Market purchase of 3,541 shares to be held as "Invested Shares" under
Executive Incentive Plan
7) Number of shares/amount of
stock acquired
3,541
8) Percentage of issued class
0.007%
9) Number of shares/amount
of stock disposed
None
10) Percentage of issued class
None
11) Class of security
Ordinary 10 pence shares
12) Price per share
£7.06
13) Date of transaction
4 March 2005
14) Date company informed
4 March 2005
15) Total holding following this notification
26,090
16) Total percentage holding of issued class following this notification
0.05%
If a director has been granted options by the company please complete the
following boxes
17) Date of grant
4 March 2005
18) Period during which or date on which exercisable
4 March 2008 to 3 March 2011
19) Total amount paid (if any) for grant of the option
Nil
20) Description of shares or debentures involved: class, number
10,623 Ordinary 10 pence shares
21) Exercise price (if fixed at time of grant) or indication that price
is to be fixed at time of exercise
10 pence per share subject to Award
22) Total number of shares or debentures over which options held
following this notification
343,566 of which:
206,974 are Options under Company Share Option Plan
92,510 are Restricted Share Awards under Executive Incentive Plan
44,082 are Matching Shares under Executive Incentive Plan
23) Any additional information
Awards granted under the Executive Incentive Plan are subject to performance
conditions
24) Name of contact and telephone number for queries
Justin Hoskins: 01223 898589
25) Name and signature of authorised company official responsible for
making this notification
Diane Mellett
Date of Notification 7 March 2005
SCHEDULE 11
NOTIFICATION OF INTERESTS OF DIRECTORS AND CONNECTED PERSONS
1) Name of company
Cambridge Antibody Technology
2) Name of director
Diane Mellett
3) Please state whether notification indicates that it is in respect of
holding of the shareholder named in 2 above or in respect of a
non-beneficial interest or in the case of an individual holder if it is a
holding of that person's spouse or children under the age of 18 or in respect of
a non-beneficial interest
As in 2 Above
4) Name of the registered holder(s) and, if more than one holder, the
number of shares held by each of them (if notified)
As in 2 above
5) Please state whether notification relates to a person(s) connected
with the Director named in 2 above and identify the connected person(s)
As in 2 above
6) Please state the nature of the transaction. For PEP transactions
please indicate whether general/single co PEP and if discretionary/non
discretionary
Market purchase of 495 shares to be held as "Invested Shares" under
Executive Incentive Plan
7) Number of shares/amount of
stock acquired
495
8) Percentage of issued class
0.001%
9) Number of shares/amount
of stock disposed
None
10) Percentage of issued class
None
11) Class of security
Ordinary 10 pence shares
12) Price per share
£7.06
13) Date of transaction
4 March 2005
14) Date company informed
4 March 2005
15) Total holding following this notification
15,062
16) Total percentage holding of issued class following this notification
0.029%
If a director has been granted options by the company please complete the
following boxes
17) Date of grant
4 March 2005
18) Period during which or date on which exercisable
4 March 2008 to 3 March 2011
19) Total amount paid (if any) for grant of the option
Nil
20) Description of shares or debentures involved: class, number
1,485 Ordinary 10 pence shares
21) Exercise price (if fixed at time of grant) or indication that price
is to be fixed at time of exercise
10 pence per share subject to Award
22) Total number of shares or debentures over which options held
following this notification
112,786 of which:
76,874 are Options under Company Share Option Plan
31,901 are Restricted Share Awards under Executive Incentive Plan
4,011 are Matching Shares under Executive Incentive Plan
23) Any additional information
Awards granted under the Executive Incentive Plan are subject to performance
conditions
24) Name of contact and telephone number for queries
Justin Hoskins: 01223 898589
25) Name and signature of authorised company official responsible for
making this notification
Diane Mellett
Date of Notification 7 March 2005
SCHEDULE 11
NOTIFICATION OF INTERESTS OF DIRECTORS AND CONNECTED PERSONS
1) Name of company
Cambridge Antibody Technology
2) Name of director
John Aston
3) Please state whether notification indicates that it is in respect of
holding of the shareholder named in 2 above or in respect of a
non-beneficial interest or in the case of an individual holder if it is a
holding of that person's spouse or children under the age of 18 or in respect of
a non-beneficial interest
As in 2 Above
4) Name of the registered holder(s) and, if more than one holder, the
number of shares held by each of them (if notified)
As in 2 above
5) Please state whether notification relates to a person(s) connected
with the Director named in 2 above and identify the connected person(s)
As in 2 above
6) Please state the nature of the transaction. For PEP transactions
please indicate whether general/single co PEP and if discretionary/non
discretionary
Market purchase of 3,541 shares to be held as "Invested Shares" under
Executive Incentive Plan at £7.06
Exercise of options over 25,000 shares at £2.87 and 9,964 shares at £2.42 of
which 22,273 shares were sold at £7.00 and 12,691 were retained.
7) Number of shares/amount of
stock acquired
38,505
8) Percentage of issued class
0.075%
9) Number of shares/amount
of stock disposed
22,273
10) Percentage of issued class
0.043%
11) Class of security
Ordinary 10 pence shares
12) Price per share
See 6 above
13) Date of transaction
4 March 2005
14) Date company informed
4 March 2005
15) Total holding following this notification
56,421
16) Total percentage holding of issued class following this notification
0.11%
If a director has been granted options by the company please complete the
following boxes
17) Date of grant
4 March 2005
18) Period during which or date on which exercisable
4 March 2008 to 3 March 2011
19) Total amount paid (if any) for grant of the option
Nil
20) Description of shares or debentures involved: class, number
10,623 Ordinary 10 pence shares
21) Exercise price (if fixed at time of grant) or indication that price
is to be fixed at time of exercise
10 pence per share subject to Award
22) Total number of shares or debentures over which options held
following this notification
125,733 of which:
51,087 are Options under Company Share Option Plan
57,765 are Restricted Share Awards under Executive Incentive Plan
16,881 are Matching Shares under Executive Incentive Plan
23) Any additional information
Awards granted under the Executive Incentive Plan are subject to performance
conditions
24) Name of contact and telephone number for queries
Justin Hoskins: 01223 898589
25) Name and signature of authorised company official responsible for
making this notification
Diane Mellett
Date of Notification 7 March 2005
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.